Health Care Technology

Allscripts-Misys (NASDAQ: MDRX) is set to close its merger with Eclipsys next week, and Auriga raised its Price Target on the stock to $21 from $20. Auriga maintains a Buy rating on the stock. In a client note, Auriga notes that "The timeline for the Allscripts-Eclipsys merger is proceeding ahead...

Shares of MedAssets Inc. (NASDAQ: MDAS) are higher on the session by 3.87%, currently trading at $20.12. The stock has been moving largely lower over the past few weeks, down from highs of $24.50 in the beginning of August. Options traders are betting that the stock sees a bit of a bounce and are...

Omnicell (Nasdaq: OMCL) today announced that Wellmont Health System has selected Omnicell OmniRx automated medication dispensing cabinets (ADCs), SinglePointe software to manage patient specific medications, Anesthesia Workstations and other solutions to streamline medication management throughout...

Volcom Inc (NASDAQ: VLCM) was upgraded by RW Baird from "neutral" to "outperform." VLCM’s shares closed at $15.39 on Friday. Volcom’s trailing-twelve-month gross margin is 50.96%. Wells Fargo Securities upgraded Emdeon Inc (NYSE: EM) from "market perform" to "outperform." EM’s shares closed at $10....

Allscripts-Misys Healthcare Solutions, Inc. (NASDAQ: MDRX) and Eclipsys Corporation (NASDAQ: ECLP) today announced that stockholders of each company approved the merger of Allscripts and Eclipsys. At the special meeting of Allscripts stockholders, held earlier today, 99% of the Allscripts shares...

Recently, Omnicell (OMCL) entered into a partnership agreement with Sentry Data Systems to co-market the latter’s Sentinel RCM application. We believe this agreement will mutually benefit both as their businesses complement each other. While Omnicell’s Workflow software caters to inventory...

Cerner Corporation (NASDAQ: CERN) is expected to gain market share, and its win-rate against Epic appears to be improving. PiperJaffray reiterates its "overweight" rating and price target of $98. Software sales are 90%+ margins, support is 76%, implementation revenue and managed services...

Oppenheimer & Co. sees an attractive entry point in shares of MedAssets, Inc. (NASDAQ: MDAS) after a slump in share price following earnings results. It has a Outperform rating and $27 price target. In the report Oppenheimer & Co. notes, "MDAS has been under pressure since reporting 2Q...

Merge Healthcare (MRGE) reported net loss per share of 39 cents in the second quarter of 2010 compared with earnings per share (EPS) of 1 cent in the year-ago period. The loss is primarily due to acquisition and restructuring costs of $5.9 million and a one-time dividend payment of $15.9 million...

Q2 Financial Review On August 5, 2010, Depomed (DEPO) reported financial results for the second quarter ended June 30, 2010. Total revenues for the second quarter were $24.4 million, an increase of 110% over the second quarter in 2009 and $0.9 million higher than our forecast of $23.5 million....

Eclipsys Corporation’s (ECLP) second-quarter fiscal 2010 adjusted earnings of 16 cents per share outshone the Zacks Consensus Estimate of 10 cents while matching the year-ago earnings. Adjusted earnings exclude special items such as restructuring charges, merger costs, amortization and adjustments...

Analysts at JP Morgan maintain their "neutral" rating on MedAssets (NASDAQ: MDAS), while reducing their estimates for the company. The target price for MDAS is set to $32. JP Morgan says, “MDAS reported 2Q non-GAAP EPS of $0.17, in line with our estimate and consensus. Total revenue was slightly...

Shares of Allscripts-Misys Healthcare Solutions (NASDAQ: MDRX) are lower on the session by 0.95%, currently trading at $16.67. The stock has been moving largely lower over the past four months and is below the 50-day and 200-day moving averages. Options traders are buying calls on the name today....

Transcend Services, Inc.’s (TRCR) share price has entered into oversold territory with a stochastic value of 16.78. The Zacks Consensus Estimate on the company’s earnings for 2010 moved up a penny over the past week to 85 cents per share. Transcend Services is a Zacks #2 Rank (“Buy”) company. ...

Jefferies & Co. is reiterating its Hold rating on shares of Computer Programs (NASDAQ: CPSI) after the healthcare information technology comapny beat quarterly earnings estimates. Jefferies has a price target of $42, below the current share price. In the note to investors Jefferies says, "...